Saxon Interests Inc. Takes Position in Moderna, Inc. $MRNA

Saxon Interests Inc. bought a new stake in Moderna, Inc. (NASDAQ:MRNA) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 11,652 shares of the company’s stock, valued at approximately $344,000.

A number of other large investors also recently made changes to their positions in MRNA. MUFG Securities EMEA plc bought a new stake in shares of Moderna in the 2nd quarter valued at approximately $28,000. Flagship Harbor Advisors LLC bought a new stake in shares of Moderna in the 4th quarter valued at approximately $31,000. Cromwell Holdings LLC grew its stake in shares of Moderna by 39.7% in the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock valued at $35,000 after buying an additional 341 shares in the last quarter. Ameriflex Group Inc. boosted its position in Moderna by 3,775.0% during the third quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock worth $32,000 after purchasing an additional 1,208 shares during the period. Finally, Kelleher Financial Advisors bought a new stake in Moderna during the fourth quarter worth approximately $39,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Up 0.5%

Shares of MRNA stock opened at $49.91 on Friday. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $59.55. The firm has a market cap of $19.80 billion, a PE ratio of -6.12 and a beta of 1.05. The stock has a 50 day moving average of $49.61 and a 200-day moving average of $44.03. The company has a quick ratio of 2.35, a current ratio of 2.41 and a debt-to-equity ratio of 0.08.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The business had revenue of $389.00 million for the quarter, compared to analyst estimates of $236.37 million. During the same quarter last year, the firm earned ($2.52) earnings per share. The firm’s quarterly revenue was up 260.2% compared to the same quarter last year. On average, equities analysts predict that Moderna, Inc. will post -6.51 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on MRNA. The Goldman Sachs Group upped their target price on Moderna from $43.00 to $49.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. Barclays upped their target price on Moderna from $25.00 to $48.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 2nd. Jefferies Financial Group set a $37.00 target price on Moderna and gave the stock a “hold” rating in a research report on Tuesday, March 3rd. Bank of America upped their target price on Moderna from $32.00 to $34.00 and gave the stock an “underperform” rating in a research report on Monday, June 8th. Finally, Evercore set a $35.00 target price on Moderna in a research report on Tuesday, February 17th. Two equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and five have given a Sell rating to the company. According to data from MarketBeat.com, Moderna has a consensus rating of “Reduce” and an average target price of $36.60.

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 3,471 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the completion of the transaction, the insider directly owned 67,468 shares in the company, valued at $3,373,400. The trade was a 4.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the company’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $48.40, for a total value of $2,581,462.40. Following the completion of the transaction, the president owned 1,477,997 shares of the company’s stock, valued at $71,535,054.80. The trade was a 3.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 71,752 shares of company stock valued at $3,453,843 in the last three months. 10.80% of the stock is owned by corporate insiders.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.